IDEXX Laboratories vs Zhonghong Pulin Medical Products: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

IDEXX Laboratories Inc (IDXX)

Q3 202621 Jul – 20 Sep 2026

▲4

IDEXX beats Q2, raises 2026 outlook, buys AI vet software

Q2 beat and raised 2026 guidance IDEXX's second-quarter revenue rose about 10% and earnings per share 18%, beating expectations, and management raised full-year EPS guidance to $14.69-$14.94. Strong recurring diagnostics demand and wider margins (35% operating) tell investors the core business is growing faster than expected, lifting the stock.
The quarter's results and guidance raise are the main new force behind IDXX's price this period.
Acquires CoVetAI to add AI scribe software IDEXX bought CoVetAI, which makes AI listening and workflow software that cuts veterinarians' paperwork. It plugs into IDEXX's software ecosystem and works with rival systems too, deepening the company's software and AI offerings and making its diagnostic tools stickier with clinics.
A new acquisition that expands IDEXX's software and AI capabilities, a fresh driver of future growth.
Reaffirms long-term growth and pipeline progress At a healthcare conference IDEXX repeated targets of over 10% organic revenue and over 15% EPS growth, with a 32%-plus operating margin. Its inVue Dx cytology tool is already hitting per-instrument revenue goals, Cancer Dx is widening to more cancers, and a new heart test launches in October.
Management's reaffirmed targets and pipeline updates give investors confidence in durable growth.
New UK tapeworm test broadens diagnostics menu IDEXX expanded its Faecal Dx antigen platform in the UK to detect taeniid tapeworm at no extra cost, now covering seven parasite groups. It strengthens the reference-lab offering and gives clinics more reasons to send tests to IDEXX, supporting recurring revenue.
A concrete product expansion that supports IDEXX's diagnostics demand and pricing power.

August 202621 Jul – 20 Sep 2026

▲4

IDEXX beats Q2, raises 2026 outlook, buys AI vet software

Q2 beat and raised 2026 guidance IDEXX's second-quarter revenue rose about 10% and earnings per share 18%, beating expectations, and management raised full-year EPS guidance to $14.69-$14.94. Strong recurring diagnostics demand and wider margins (35% operating) tell investors the core business is growing faster than expected, lifting the stock.
The quarter's results and guidance raise are the main new force behind IDXX's price this period.
Acquires CoVetAI to add AI scribe software IDEXX bought CoVetAI, which makes AI listening and workflow software that cuts veterinarians' paperwork. It plugs into IDEXX's software ecosystem and works with rival systems too, deepening the company's software and AI offerings and making its diagnostic tools stickier with clinics.
A new acquisition that expands IDEXX's software and AI capabilities, a fresh driver of future growth.
Reaffirms long-term growth and pipeline progress At a healthcare conference IDEXX repeated targets of over 10% organic revenue and over 15% EPS growth, with a 32%-plus operating margin. Its inVue Dx cytology tool is already hitting per-instrument revenue goals, Cancer Dx is widening to more cancers, and a new heart test launches in October.
Management's reaffirmed targets and pipeline updates give investors confidence in durable growth.
New UK tapeworm test broadens diagnostics menu IDEXX expanded its Faecal Dx antigen platform in the UK to detect taeniid tapeworm at no extra cost, now covering seven parasite groups. It strengthens the reference-lab offering and gives clinics more reasons to send tests to IDEXX, supporting recurring revenue.
A concrete product expansion that supports IDEXX's diagnostics demand and pricing power.

Latest21 Jul – 20 Sep 2026

▲4

IDEXX beats Q2, raises 2026 outlook, buys AI vet software

Q2 beat and raised 2026 guidance IDEXX's second-quarter revenue rose about 10% and earnings per share 18%, beating expectations, and management raised full-year EPS guidance to $14.69-$14.94. Strong recurring diagnostics demand and wider margins (35% operating) tell investors the core business is growing faster than expected, lifting the stock.
The quarter's results and guidance raise are the main new force behind IDXX's price this period.
Acquires CoVetAI to add AI scribe software IDEXX bought CoVetAI, which makes AI listening and workflow software that cuts veterinarians' paperwork. It plugs into IDEXX's software ecosystem and works with rival systems too, deepening the company's software and AI offerings and making its diagnostic tools stickier with clinics.
A new acquisition that expands IDEXX's software and AI capabilities, a fresh driver of future growth.
Reaffirms long-term growth and pipeline progress At a healthcare conference IDEXX repeated targets of over 10% organic revenue and over 15% EPS growth, with a 32%-plus operating margin. Its inVue Dx cytology tool is already hitting per-instrument revenue goals, Cancer Dx is widening to more cancers, and a new heart test launches in October.
Management's reaffirmed targets and pipeline updates give investors confidence in durable growth.
New UK tapeworm test broadens diagnostics menu IDEXX expanded its Faecal Dx antigen platform in the UK to detect taeniid tapeworm at no extra cost, now covering seven parasite groups. It strengthens the reference-lab offering and gives clinics more reasons to send tests to IDEXX, supporting recurring revenue.
A concrete product expansion that supports IDEXX's diagnostics demand and pricing power.

Zhonghong Pulin Medical Products Co. Ltd. (300981.CS)

Q3 202628 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.

August 202628 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.

Latest28 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.